Post-earnings recap
Reported
Thu, Mar 28, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kodiak Sciences reported a loss per share of $0.40, but did not provide revenue figures or future guidance. The stock reacted negatively, declining by 0.75%. The lack of specific guidance may have raised concerns among investors about the company's near-term prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.40 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management expressed a commitment to its ongoing clinical trials. However, they did not provide any updates on future guidance, which may have contributed to investor caution.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its clinical programs.